At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Esomeprazole +1 moredrug
Likely dose
Esomeprazole 40 mg once dailyAI-extracted
Key inclusion· 4
- ✓Age 18-55 years
- ✓Moderate to severe epigastric pain/discomfort in upper abdomen as dominant symptom
- ✓Epigastric pain/discomfort present at least 3 times per week for 12 weeks
- ✓Willing and able to provide informed consent and comply with study requirements
Key exclusion· 9
- ✕H. pylori positive serology
- ✕Regular use of NSAIDs or more than 100 mg of aspirin
- ✕History or presence of esophagitis, gastric ulcer, duodenal ulcer, or duodenal erosions on endoscopy/radiology
- ✕History of or prior upper GI surgery
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhibition of Gastric Acid Is the Key To Satisfactory Relief of Symptoms and Restoration of the Quality of Life in Patients With Epigastric Pain Related to Non-Ulcer Dyspepsia During Therapy With Esomeprazole
In Brief
A Phase 2 clinical trial evaluating Esomeprazole and Placebo for Indigestion. Completed, enrolled 73 participants across 1 site.
Detailed Summary
Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIndigestion
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2003
First PostedSep 2005
Primary CompletionJan 2008
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartOct 1, 2003
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.8 years ago
Interventions
Esomeprazoledrug
Esomeprazole 40 mg QD
Placeboother
Placebo